GSK Spreads Smoking-Cessation Aids To Countries Serious About Quitting
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline plans to introduce its smoking-cessation products to 800 million people over the next four years in countries working to reduce smoking among their populations
You may also be interested in...
Tobacco Oversight Looks More Likely, But Is It Bad For FDA’s Health?
The likelihood of Congress handing FDA responsibility for regulating tobacco has ignited debate over whether the new purview would distract an already struggling agency from its mission
GSK Invests In Consumer Unit To Overcome Generic Threat, Low Alli Sales
GlaxoSmithKline expects to overcome increasing generic competition by growing its consumer health business and investing in emerging markets, rather than by pursuing a mega-merger like Pfizer-Wyeth
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.